Dysregulation of the mTOR Pathway Mediates Impairment of Synaptic Plasticity in a Mouse Model of Alzheimer's Disease-Reference-Cited by-同舟云学术

Dysregulation of the mTOR Pathway Mediates Impairment of Synaptic Plasticity in a Mouse Model of Alzheimer's Disease

Published:2010-09-20 Issue:9 Volume:5 Page:e12845
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Ma Tao,Hoeffer Charles A.,Capetillo-Zarate Estibaliz,Yu Fangmin,Wong Helen,Lin Michael T.,Tampellini Davide,Klann Eric,Blitzer Robert D.,Gouras Gunnar K.

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference49 articles.

1. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide.;C Haass;Nat Rev Mol Cell Biol,2007

2. Alzheimer's disease.;HW Querfurth;N Engl J Med,2010

3. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction.;S Oddo;Neuron,2003

4. A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo.;T Tomiyama;J Neurosci,2010

5. Expanding mTOR signaling.;Q Yang;Cell Res,2007

Cited by 211 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In Silico Prediction of Quercetin Analogs for Targeting Death-Associated Protein Kinase 1 (DAPK1) Against Alzheimer’s Disease;Current Neuropharmacology;2024-12

2. Delineation of the role of G6PD in Alzheimer’s disease and potential enhancement through microfluidic and nanoparticle approaches;Ageing Research Reviews;2024-08

3. Unraveling the role of plasma proteins in dementia: insights from two cohort studies in the UK, with causal evidence from Mendelian randomization;2024-06-04

4. Native-state proteomics of Parvalbumin interneurons identifies unique molecular signatures and vulnerabilities to early Alzheimer’s pathology;Nature Communications;2024-04-01

5. Memantine: Updating a rare success story in pro-cognitive therapeutics;Neuropharmacology;2024-02